BioCentury
ARTICLE | Clinical News

Acadra acadesine: Phase I/IIa data

February 28, 2011 8:00 AM UTC

An open-label, dose-escalation, European Phase I/IIa trial in 24 patients with relapsed or refractory CLL showed that Acadra was well tolerated and led to reductions in leukemic tumor burden. Addition...